The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work ...

The strategic decision to end further internal development of the ex-Novartis asset, dubbed naporafenib, will allow Erasca to ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

An appeals court has opened another chapter in the long-running CRISPR patent saga. | An appeals court has opened another ...

The uncertainty around splitting up the business is only the latest in a series of strategic shake-ups at Galapagos in recent ...

Roche plans to invest as much as $550 million in its Indianapolis diagnostics campus during the next five years, with plans to build it into a U.S. | The announcement follows a five-year, $50-billion ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...